CRT 2026

Discussion: Clinical Experience and Implications Using Both LithiX and Bioadaptor

Moderator(s)

• 

  Dean J. Kereiakes, MD, FACC, MSCAI

  Chairman, The Christ Hospital Heart and Vascular Institute; Medical Director, The Christ Hospital Research Institute; Professor of Clinical Medicine, The Ohio State University
  The Christ Hospital Health Network
  Cincinnati, Ohio, United States

  Disclosure(s): Ablative Solutions, Inc.: Stock Options [in privately held companies] (Ongoing); CeleCor Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Egg Medical, Inc: Stock Options [in privately held companies] (Ongoing); Elixir Medical Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Foldax: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Sino Medical Sciences Technology, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing)

Panel Discussant(s)

• 

  Hector M. Garcia-Garcia, MD, PhD

  Director of Invasive Imaging Core Laboratory
  MedStar Washington Hospital Center
  Washington, District of Columbia, United States

  Disclosure information not submitted.
• 

  Shigeru Saito, MD, FACC, FSCAI

  Director, Heart Center
  Shonan Kamakura General Hospital
  Kamakura, Kanagawa, Japan

  Disclosure(s): Elixir Medical: Consulting Fees (e.g., advisory boards) (Ongoing)